

**Maryland Board of Pharmacy  
Public Board Meeting**

**Agenda  
November 20, 2024**

Name	Title	Present	Absent
Evans, K.	Commissioner		
Fink, K.	Commissioner		
Geigher, P.	Commissioner/Treasurer		
Hardesty, J.	Commissioner		
Leikach, N.	Commissioner		
Masood, M.	Commissioner		
Oliver, B.	Commissioner		
Oriafo, A.	Commissioner		
Patel, A.	Commissioner		
Robinson, D.	Commissioner/Pharmacy Technician		
Rusinko, K.	Commissioner/President		
Slagle, K.	Commissioner		
Vázquez, J.	Commissioner/Secretary		
Bethman, L.	Board Counsel		
Felter, B.	Board Counsel		
Speights-Napata, D.	Executive Director		
Partin, J.	Director of IT, Budget & Procurement		
Vacant	Licensing Manager		
Leak, T.	Compliance Director		
Gaskins, J.	Legislative Liaison		
Watts-Vess, S	Communications Manager		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

I. Executive Committee Report(s)	<p>A.) K. Rusinko, Board President</p> <p>B.) J. Vazquez, Secretary</p>	<p><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <ol style="list-style-type: none"> <li>1. Call to Order</li> <li>2. Sign-in Introduction and of meeting attendees – <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i></li> <li>3. Distribution of Agenda and packet materials</li> <li>4. Review and approve <b>October 2024</b> Public Meeting Minutes</li> </ol>																					
II. A. Executive Director Report	D. Speights-Napata Executive Director	<ol style="list-style-type: none"> <li>1. Meeting Update</li> <li>2. Staff Update</li> </ol>																					
B. New Business	K. Rusinko, Board President																						
C. Operations	J. Partin, IT Director Budget & Procurement	<ol style="list-style-type: none"> <li>1. Procurement and Budget Updates               <ol style="list-style-type: none"> <li>a. <b>October Financials</b></li> </ol> </li> <li>2. Management Information Systems (MIS) Unit Updates</li> </ol>																					
D. Licensing	K. Slagle, Chair	<table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td colspan="5" style="padding: 5px;"><b>1. Unit Updates</b></td> </tr> <tr> <td colspan="5" style="padding: 5px;"><b>2. Monthly Statistics</b></td> </tr> <tr> <td style="padding: 5px; text-align: center;">License Type</td> <td style="padding: 5px; text-align: center;">New</td> <td style="padding: 5px; text-align: center;">Renewed</td> <td style="padding: 5px; text-align: center;">Reinstated</td> <td style="padding: 5px; text-align: center;">Total</td> </tr> <tr> <td style="padding: 5px; text-align: center;">Distributor</td> <td style="padding: 5px; text-align: center;">19</td> <td style="padding: 5px; text-align: center;">0</td> <td style="padding: 5px; text-align: center;">0</td> <td style="padding: 5px; text-align: center;">1,574</td> </tr> </tbody> </table>	<b>1. Unit Updates</b>					<b>2. Monthly Statistics</b>					License Type	New	Renewed	Reinstated	Total	Distributor	19	0	0	1,574	
<b>1. Unit Updates</b>																							
<b>2. Monthly Statistics</b>																							
License Type	New	Renewed	Reinstated	Total																			
Distributor	19	0	0	1,574																			

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<table border="1"> <tbody> <tr> <td>Pharmacy</td> <td>13</td> <td>0</td> <td>0</td> <td>2,176</td> </tr> <tr> <td>Pharmacist</td> <td>45</td> <td>376</td> <td>4</td> <td>12,821</td> </tr> <tr> <td>Vaccination</td> <td>18</td> <td>169</td> <td>0</td> <td>5,293</td> </tr> <tr> <td>Pharmacy Intern - Graduate</td> <td>2</td> <td>0</td> <td>0</td> <td>33</td> </tr> <tr> <td>Pharmacy Intern – Student</td> <td>5</td> <td>3</td> <td>0</td> <td>377</td> </tr> <tr> <td>Pharmacy Technician</td> <td>124</td> <td>313</td> <td>4</td> <td>10,595</td> </tr> <tr> <td>Pharmacy Technician-Student</td> <td>4</td> <td>0</td> <td>0</td> <td>33</td> </tr> <tr> <td><b>TOTAL</b></td> <td><b>230</b></td> <td><b>861</b></td> <td><b>8</b></td> <td><b>33,131</b></td> </tr> </tbody> </table>	Pharmacy	13	0	0	2,176	Pharmacist	45	376	4	12,821	Vaccination	18	169	0	5,293	Pharmacy Intern - Graduate	2	0	0	33	Pharmacy Intern – Student	5	3	0	377	Pharmacy Technician	124	313	4	10,595	Pharmacy Technician-Student	4	0	0	33	<b>TOTAL</b>	<b>230</b>	<b>861</b>	<b>8</b>	<b>33,131</b>	
Pharmacy	13	0	0	2,176																																							
Pharmacist	45	376	4	12,821																																							
Vaccination	18	169	0	5,293																																							
Pharmacy Intern - Graduate	2	0	0	33																																							
Pharmacy Intern – Student	5	3	0	377																																							
Pharmacy Technician	124	313	4	10,595																																							
Pharmacy Technician-Student	4	0	0	33																																							
<b>TOTAL</b>	<b>230</b>	<b>861</b>	<b>8</b>	<b>33,131</b>																																							
<b>E. Compliance</b>	<b>T. Leak, Compliance Director</b>	<p><b>1. Unit Updates</b></p> <p><b>2. Monthly Statistics</b></p> <p><b>Complaints &amp; Investigations:</b></p> <p>New Complaints- 49</p> <ul style="list-style-type: none"> <li>· Inspection Issues- 25</li> <li>· Medication Error- 4</li> </ul>																																									

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<ul style="list-style-type: none"> <li>· Out of State Disciplinary Actions-11</li> <li>· Unprofessional Conduct- 2</li> <li>· Customer Service-3</li> <li>· Red Flag- 2</li> <li>· Other- 2</li> </ul> <p>(25-108- DEA 106 form indicates that the pharmacist mistakenly put a return to sender bottle in customer bag)</p> <p>(25-114- Narcotic discrepancy self report- so far no new knowledge about where and how the loss occurred)</p> <p>Resolved- 30            Actions within Goal- 30/30            Formal (Final) Disciplinary Actions Taken- 7            Summary Actions Taken- 1            Average Days to Complete- 76</p> <p><b>Regulatory Inspections:</b>            Total - <b>146</b>            Annual Inspections - <b>134</b></p> <ul style="list-style-type: none"> <li>● Chain - 51</li> <li>● Independent - 25</li> <li>● Sterile Compounding - 13</li> <li>● Repository - 17</li> <li>● Comprehensive Care - 1</li> <li>● Hospital - 8</li> <li>● Supplemental Assisted Living - 3</li> </ul>	
--	--	---	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<ul style="list-style-type: none"> <li>● Follow up - 0</li> <li>● Distributor - 13</li> <li>● Attempted- 3</li> </ul> <p>Openings/Remodels/Relocations - 9            Closing Inspections - 2            Change of Ownership - 1  <b>Pending Opening – 1</b>  <b>Pending Closing - 5</b></p>	
<b>F. Legislation &amp; Regulations</b>	<b>J. Gaskins, Legislative Liaison</b>	<u><b>Legislation</b></u>  The Legislative Committee had their first meeting on November 15, 2024 to prepare the 2025 Legislative Agenda.  <u><b>Regulations</b></u>	
<b>III. Committee Reports</b>  <b>A. Practice Committee</b>	<b>K, Evans, Chair</b>	<p>Q1) J. Obong - Hi, our organization is in the process of conducting research on asthmatic pediatric patients who are admitted as inpatients and started on albuterol metered dose inhaler (MDI). What the doctors are asking is for pharmacies to discharge these patients home with the same albuterol inhaler they used while admitted in the hospital. While these patients are admitted in the hospital, pharmacies label the inhalers with labels that meet BOP Inpatient labeling requirements.</p> <p>The challenge now becomes, discharging these patients with these same inhalers. This is the plan we want to put forth and need BOP guidance.</p> <ol style="list-style-type: none"> <li>1. During patient discharge, a nurse or doctor will remove the inpatient label from the inhaler and affix a generic pharmacy preprinted outpatient label (these labels meet BOP outpatient labeling requirements). The Doctor/Nurse will fill out the patient name and all pertinent information needed on the label. The doctor will hand the inhaler to the</li> </ol>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<p>patient/caregiver making sure the patient receives discharge instructions and education.</p> <p><u>Question: Is it within the scope of practice or is it within the BOP requirements for nursing or doctors to remove the inpatient label and affix an outpatient label to these inhalers before patients are discharged home with them or MUST this labeling step be completed only by a pharmacist?</u></p> <p><u>Alternative plan</u></p> <ol style="list-style-type: none"> <li>1. At discharge the nurse brings an inhaler to the pharmacy.</li> <li>2. Pharmacist removes the inpatient label and relabels with outpatient label filling out all pertinent information on the outpatient label.</li> <li>3. The nurse returns an outpatient labeled inhaler to the Doctor.</li> <li>4. The doctor dispenses the outpatient labeled inhaler to the patient/caregiver.</li> <li>5. Doctor/Nurse completes patient instructions and education.</li> </ol> <p><b>Response: No, the Board of Pharmacy does not regulate the practice of medicine or nursing.</b></p> <p><b>Alternative 2 falls in line with the scope of practice for pharmacists operating pharmacies in Maryland.</b></p> <p>Q2) J. Falkenrath - If a repackaging company, that engages in repackaging at the direction of their client, (they do not take ownership of the product) is directed to ship the product (prescription drugs) on behalf of the owner of the products into the state of Maryland, would you require the repackager to hold a license?</p> <p><b>Response: Yes, a distributor permit would be required.</b></p> <p>Q3) T. Gurss - I wanted to reach out to ask about the Maryland Board of Pharmacy's stance on operating multiple pharmacies out of a single</p>	
--	--	---	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

	<p><b>Commissioners C. Rusinko &amp; J. Vázquez Recused</b></p>	<p>facility. Certain states allow multiple pharmacies to operate out of the same space/address as long as they have segregated inventory, inventory management, and licensing. Is that the case for Maryland as well?</p> <p><b>Response: A full-service and a waiver can operate in conformance with COMAR 10.34.17.04</b></p> <p style="text-align: center;"><b><u>Drug Therapy Management Programs</u></b></p> <p><b><u>Pharmacy:</u></b> Chase Brexton</p> <p><b><u>Pharmacists:</u></b> Natalie Gordon</p> <p><b><u>Protocols:</u></b> Tobacco Cessation and Metabolic Syndrome</p> <p><b><u>Pharmacy:</u></b> Johns Hopkins</p> <p><b><u>Pharmacists:</u></b> Maxwell Ditlevson</p> <p><b><u>Protocols:</u></b> Diabetes Pharmacotherapy, Hypertension Pharmacotherapy, Heart Failure Pharmacotherapy,</p>	
--	---	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

	<p><b>Commissioners C. Rusinko &amp; J. Vázquez Recused</b></p> <p><b>Commissioners C. Rusinko &amp; J. Vázquez Recused</b></p> <p><b>Commissioners C. Rusinko &amp; J. Vázquez Recused</b></p>	<p>Cardiovascular Risk Reduction and Obesity Pharmacotherapy</p> <p><b><u>Pharmacy:</u></b> Johns Hopkins</p> <p><b><u>Pharmacists:</u></b> Lindsey Toman</p> <p><b><u>Protocols:</u></b> Cardiovascular Risk Reduction, Diabetes, Hypertension and Management of Acid Suppressing Pharmacotherapy</p> <p><b><u>Pharmacy:</u></b> Johns Hopkins</p> <p><b><u>Pharmacists:</u></b> Jessica Merrey and Katharine Russo</p> <p><b><u>Protocols:</u></b> Asthma, COPD, Heart Failure, Non-Opioid Pain Management and Obesity</p> <p><b><u>Pharmacy:</u></b> Johns Hopkins</p> <p><b><u>Pharmacists:</u></b> Sierra McNew</p> <p><b><u>Protocols:</u></b> Antithrombotics, Parental Nutrition, Therapeutic Drug Monitoring and Renal Dose Adjustment</p>	
--	---	---	--



Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

<p><b>B. Licensing Committee</b></p>	<p><b>K. Slagle, Chair</b></p>	<p><b>1. Review of Pharmacist Applications:</b></p> <ul style="list-style-type: none"> <li>a. <b>Y.A.:</b> The applicant is requesting an extension of the ATT approval that will expire on January 3, 2025 as she is still preparing to take the NAPLEX in March 2025. <u><i>Committee Recommendation: Approve</i></u></li> <li>b. <b>M.Q.:</b> The applicant is requesting to retake the NAPLEX for the sixth attempt. <u><i>Committee Recommendation: Approve. Submit a pharmacist application.</i></u></li> <li>c. <b>E.B.:</b> The applicant is requesting to retake the MPJE for the sixth attempt. <u><i>Committee Recommendation: Approve. Submit a pharmacist application.</i></u></li> </ul> <p><b>2. Review of Pharmacist Renewal Applications: None</b></p> <p><b>3. Review of Pharmacist Reinstatement Applications: None</b></p> <p><b>4. Review of Technician Applications: None</b></p> <p><b>5. Review of Technician Reinstatement Applications: None</b></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<p><b>6. Review of Intern New Applications: None</b></p> <p><b>7. Review of Intern Renewal Applications: None</b></p> <p>a. <b>A.O.:</b> The applicant is requesting an extension on their pharmacy intern license with an expiration date of November 30, 2024 and to extend NAPLEX ATT that expires January 20, 2025 due to unforeseen family and medical issues. <u><b>Licensing Committee Recommendation: Approve. Extend until January 31, 2025. Applicant must reapply and pay the fee to take the NAPLEX.</b></u></p> <p><b>8. Review of Pharmacy Applications: None</b></p> <p><b>9. Review of Distributor Renewal Applications:</b></p> <p>a. <b>D02407:</b> The permit holder is changing their Designated Representative and is requesting to use federal and state background checks for their new Designated Representative dated from 2023. <u><b>Licensing Committee Recommendation: Deny. Federal and state background results for the Designated Representative must be dated within 6 months.</b></u></p> <p><b>10. Review of Continuing Education Program Request:</b></p> <p>a. <b>Pharmaceutical and Supply Chain Management: Realities from the Field</b> <i>Requesting (4) hours</i> <u><b>Committee Recommendation: Deny</b></u></p> <p>b. <b>Bridging the Care Gap in CKD-associated Pruritis: Using QI and Change Management to Address Assessment and Management</b> <i>Requesting (1.75) hours</i> <u><b>Committee Recommendation: Deny</b></u></p>	
--	--	---	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<p><b>c. Medical Countermeasures: Point of Dispensing, Planning, and Response - MGT-319 Requesting (16) hours</b>  <b><u>Committee Recommendation:</u> Approve</b></p> <p><b>11. Review of Pharmacy Technicians Training Program: None</b></p> <p><b>11. New Business: None</b></p>	
<b>C. Public Relations Committee</b>	<b>J. Vázquez, Chair</b>	<b>Public Relations Committee Update:</b>	
<b>D. Disciplinary</b>	<b>K. Fink, Chair</b>	<b>Disciplinary Committee Update</b>	
<b>E. Emergency Preparedness Task Force</b>	<b>N. Leikach, Chair</b>	<b>Emergency Preparedness Task Force Update</b>	
<b>IV. Other Business &amp; FYI</b>	<b>K. Rusinko, President</b>		
<b>V. Adjournment</b>	<b>K. Rusinko, President</b>	<p><b>A. The Public Meeting was adjourned</b></p> <p><b>B. I would like to ask for a motion to close the public meeting and open a closed public session for the purpose of engaging in medical review committee deliberations of confidential matters contained in licensure applications in accordance with General Provisions Article Section 3-305(b)(13).</b></p> <p><b>C. Immediately thereafter, K. Rusinko, convened an Administrative Session for purposes of discussing confidential disciplinary cases.</b></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<p><b>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Administrative Session.</b></p>	
--	--	--	--